Tru Singular Health, Inc. has announced the successful completion of a private offering, raising a total of $1 million. This funding was secured through Simple Agreements for Future Equity (SAFE), a method increasingly favored in the biotechnology sector for its flexibility and efficiency.

The offering, which was filed on October 30, 2026, is significant not just for the company but also for the broader industry, as it indicates a shift towards innovative funding strategies among biotech firms.

Background

Tru Singular Health, Inc. is a corporation incorporated in Delaware, with its business address located at 27B Woodland St., Natick, Massachusetts. The company is categorized under the biotechnology industry group. The firm filed its most recent Form D on October 30, 2026, indicating its ongoing efforts to secure funding for its initiatives.

What the Filing Says

According to the SEC filing, the company has successfully sold the entire offering amount of $1 million. The filing states, "totalOfferingAmount" as $1,000,000 and "totalAmountSold" as $1,000,000, highlighting that all available securities were sold.

Impact

This funding will likely impact the 12 accredited investors who participated in the offering, as they will now hold stakes in Tru Singular Health. The successful completion of this offering positions the company to advance its projects within the competitive biotechnology landscape.

What's Next

The filing does not say what happens next.